Complex molecules – current developments
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 2
Abstract
The pharmacological activity and toxicity of non-biological complex drugs (NBCDs) depends on their complex structure and composition. The regulatory approach leading to the registration of such drugs and their follow-on products, deemed ‘nanosimilars’, must be based on emerging scientific knowledge of NBCD properties determining their in vivo fate.
Authors and Affiliations
Gerrit Borchard
Keywords
Related Articles
- EP ID EP354314
- DOI 10.5639/gabij.2014.0302.016
- Views 129
- Downloads 0
Complex molecules – current developments
The pharmacological activity and toxicity of non-biological complex drugs (NBCDs) depends on their complex structure and composition. The regulatory approach leading to the registration of such drugs and their follow-on...
Latest features in GaBI Journal, 2013, Issue 3
The GaBI Journal again contains manuscripts covering a wide range of pertinent topics. In an Editorial, Dr Gianluigi Casadei reviews Italy’s final position paper on biosimilars including the new price and reimbursement p...
Latest features in GaBI Journal, 2012, issue 3-4
This issue of the GaBI Journal uses a number of article formats to cover a range of issues related to generics and biosimilars.
Pharmacovigilance of biosimilars: challenges and possible solutions
Post-marketing surveillance is essential to detect, assess and prevent adverse reactions of chemically synthesized small molecule drugs as well as biologicals, as the full safety profile can only be known after they have...
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price and volu...